Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    21639808 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Conditions: Metastatic Cancer;   Melanoma
Interventions: Drug: Vemurafenib;   Biological: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
2 Completed
Has Results
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Condition: Malignant Melanoma
Interventions: Drug: Vemurafenib;   Drug: Dacarbazine
3 Recruiting Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Condition: Melanoma
Intervention: Drug: vemurafenib and cobimetinib
4 Active, not recruiting The Oncopanel Pilot (TOP) Study
Conditions: Colorectal Cancer Metastatic;   Advanced Non-Small Cell Lung Carcinoma;   Advanced Melanoma;   Gastrointestinal Stromal Tumors;   Patients With Diagnosed Malignancies Being Considered for Clinical Trials
Intervention:
5 Recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
6 Recruiting Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Condition: Neoplasms
Intervention: Genetic: Blood and tumor samples

Study has passed its completion date and status has not been verified in more than two years.